Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Apple Turns 50: From Garage Startup to AI Crossroads 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
NEW YORK, Sept. 05, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Foundation Medicine, Inc. ("Foundation") (NASDAQ:FMI) securities between February 26, 2014 and November 3, 2015.
Click here to learn about the case: http://www.wongesq.com/pslra-sbm/foundation-medicine-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose material information regarding: (1) the reimbursement process and likelihood of coverage for Foundation’s tumor tests by Medicare; and (2) the Company’s financial guidance. As a result of these false statements, Foundation common stock traded at artificially inflated prices during the Class Period.
On July 29, 2015, the Company disclosed that it was not making the strides obtaining coverage it had claimed to have been making during the Class Period, and that Foundation would receive no Medicare payments in 2015 for its tumor profiling tests due to a delay in receiving a local coverage determination from its regional Medicare Administrative Contractor. As a result of the delay, the Company slashed its 2015 financial guidance, which, unbeknownst to investors, was based on an assumption that Medicare approval was going to be obtained in 2015. Then, on November 3, 2015, the Company disclosed a further revision to the already reduced number of clinical tests it expected to report for 2015. Following this disclosure, the price of Foundation common stock fell to a close of $17.31 per share on November 4, 2015.
If you suffered a loss in Foundation you have until September 26, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/foundation-medicine-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
